Acrux Limited · ASX:ACR
Acrux — H1 FY2015 Earnings Presentation
11 slides from Acrux's earnings presentation, Feb 26, 2015
Slide 1: HY15 Results Presentation
For personal use only Acrux (ASX: ACR) HY15 Results Presentation 26 February, 2015 Michael Kotsanis – Chief Executive Officer Sharon Papworth – Chief Financial Officer
Slide 2: Forward Looking Statements
Forward Looking Statements For personal use only This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Acrux to be mate
Slide 3: Summary of Financials
Summary of Financials Profitable and with a strong balance sheet to execute our future growth strategy, For personal use only aimed to provide income diversification and shareholder return • Total revenue $14.2m, down 67.5% on prior year – Nil Product Milestones received, $28.8m received in the prio
Slide 4: Axiron® - United States
Axiron® - United States Highlights For personal use only • Market share consistent throughout 2014 • share of market for December 2014 was 13.9% • sales volume decline in US market partially offset by increased net realised price • Second largest (in US$) brand in US testosterone replacement market
Slide 5: Axiron® - United States (continued)
Axiron® - United States (continued) For personal use only Axiron volume and growth • Axiron volume stabilising over recent months • Market declines have slowed for the topical testosterone market and for Axiron • Future market direction dependent on FDA Statement Volume growth Volume decline FDA Saf
Slide 6: Axiron® - Rest of World
Axiron® - Rest of World For personal use only Highlights • Strong volume growth in launched markets • European Medicines Agency testosterone statement released in November, 2014 Outlook • Continued revenue growth across countries where Axiron has been launched 6 Source: Lilly Q4 Results – Financial
Slide 7: Key Financials
Key Financials • Revenue of $14.2m, down 67.5% on pcp For personal use only - Nil Milestone revenue generated (pcp $28.8m) A$m 31 Dec 31 Dec % - Royalty income driven by testosterone 2014 2013 Decline market decline in the US Product Royalties 13.7 14.5 5.5% Product Milestones & 0.5 29.2 98.3% • Ope
Slide 8: Cash Flow
Cash Flow For personal use only • Cash and cash equivalents $15.8m at 31 Cash flow by category: period ended December 2014 31 December 2014 40,000 35,000 30,000 • Operating cash inflow $3.2M, comprising 25,000 • Royalty receipts $11.1M 20,000 15,000 • Interest on cash investment $0.4M 10,000 5,000 •
Slide 9: Pipeline Update
Pipeline Update For personal use only • Ellavie® - Europe: • Gedeon Richter continues on track for launch in Europe • Aspen achieved regulatory approval in South Africa • Active program to in-license or acquire new technologies • Unique pain and inflammation product concepts in early testing • addit
Slide 10: For personal use only
For personal use only
Slide 11: Appendix – Acrux at a glance
Appendix – Acrux (ASX: ACR) at a glance • Market cap ~A$220 million1 For personal use only • Unique, patented technology for delivering drugs through the skin • Products developed by Acrux, approved and launched in major markets: 1. Axiron®, marketed by Lilly for hypogonadism in the US and other ter